Trial Profile

Phase I study of TAS-116 in combination with Nivolumab in patients with progressive or metastatic solid cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Pimitespib (Primary)
Indications Biliary cancer; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
Focus Adverse reactions
Acronyms TAS116nivo_study

Most Recent Events

30 Sep 2021 Results assessing safety and efficacy of TAS-116 plus nivolumab for CRC and other solid tumors.published in the Clinical Cancer Research
22 Feb 2021 Status changed from active, no longer recruiting to completed.
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com